Compare USPH & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USPH | SPRY |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1992 | N/A |
| Metric | USPH | SPRY |
|---|---|---|
| Price | $81.66 | $11.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $106.50 | $31.25 |
| AVG Volume (30 Days) | 190.5K | ★ 1.6M |
| Earning Date | 02-25-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ 153.49 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $750,948,000.00 | $142,772,000.00 |
| Revenue This Year | $19.53 | N/A |
| Revenue Next Year | $6.33 | $127.81 |
| P/E Ratio | $33.44 | ★ N/A |
| Revenue Growth | 17.51 | ★ 5459.66 |
| 52 Week Low | $62.77 | $6.66 |
| 52 Week High | $93.50 | $18.90 |
| Indicator | USPH | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 55.38 |
| Support Level | $78.61 | $10.85 |
| Resistance Level | $85.40 | $11.43 |
| Average True Range (ATR) | 3.31 | 0.60 |
| MACD | 0.09 | -0.07 |
| Stochastic Oscillator | 52.66 | 57.47 |
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.